Active, not recruitingPhase 1NCT04844619
KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
Studying Neovascular glaucoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sun Yat-sen University
- Principal Investigator
- Xiulan Zhang, MD, PhDZhongshan Ophthalmic Center, Sun Yat-sen University
- Intervention
- 4mg/ml KDR2-2 suspension eyedrop(drug)
- Enrollment
- 40 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2021 – 2024
Study locations (1)
- Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04844619 on ClinicalTrials.govOther trials for Neovascular glaucoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT07201415Minimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular GlaucomaZhongnan Hospital
- ACTIVE NOT RECRUITINGNANCT05316142Effect of Subconjunctival 5-fluorouracil on the Outcome of Ahmed Valve in Neovascular GlaucomaIran University of Medical Sciences
- RECRUITINGNCT04519619Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)Bayer